Physician attitudes and practice toward human papillomavirus vaccination

Journal of Lower Genital Tract Disease

Volumn 14, Issue 4, 2010, Pages 339-345

  Ko, Emily M ^a   Missmer, Stacey ^a   Johnson, Natasha R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Barrier; HPV; human papillomavirus; physician; vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; PHYSICIAN ATTITUDE; PRIVATE PRACTICE; REIMBURSEMENT; VACCINATION; WART VIRUS;

ATTITUDE OF HEALTH PERSONNEL; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; HUMANS; INTERNET; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHYSICIANS; QUESTIONNAIRES;

EID: 77958119045     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e3181dca59c     Document Type: Article

References (22)

1. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
2. Torne A, Alonso I, Puig-Tintore LM, Pahisa J. Clinical role of cervical cancer vaccination: when and whom to vaccinate? Gynecol Oncol 2008;110(3 suppl 2):S15-6.
3. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007;45:107-14.
4. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirusYrelated disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107-22.
5. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
6. Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, et al. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol 2006;102:552-62. (Pubitemid 44354954)
7. Herzog TJ, Huh WK, Downs LS, Smith JS, Monk BJ. Initial lessons learned in HPV vaccination. Gynecol Oncol 2008;109(suppl 2):S4-11.
8. Monk BJ, Herzog TJ. The new era of cervical cancer prevention: HPV vaccination. Gynecol Oncol 2008; 109(suppl 2):S1-3. (Pubitemid 351649369)
9. Esposito S, Bosis S, Pelucchi C, Begliatti E, Rognoni A, Bellasio M, et al. Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention. Vaccine 2007;25:6437-46. (Pubitemid 47202049)
10. Kahn JA, Zimet GD, Bernstein DI, Riedesel JM, Lan D, Huang B, et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health 2005;37:502-10. (Pubitemid 41681772)
11. Raley JC, Followwill KA, Zimet GD, Ault KA. Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists. Infect Dis Obstet Gynecol 2004;12:127-33.
12. Rothman DJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia, PA: Wolters Kluwer Health/ Lippincott Williams & Wilkins; 2008.
13. Feemster KA, Winters SE, Fiks AG, Kinsman S, Kahn JA. Pediatricians' intention to recommend human papillomavirus (HPV) vaccines to 11- to 12-year-old girls postlicensing. J Adolesc Health 2008;43:408-11.
14. Riedesel JM, Rosenthal SL, Zimet GD, Bernstein DI, Huang B, Lan D, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol 2005;18:391-8. (Pubitemid 41773995)
15. CDC. Press Release. Nation's teen vaccination coverage increasing, but below 2010 goals. Survey provides first estimates for HPV vaccination. 2008. Available at: http:// www.cdc.gov/media/pressrel/2008/r081009.htm. Accessed November 27, 2008.
16. CDC. Vaccines for Children Program (VFC). 2008. Available at: http://www.cdc.gov/vaccines/programs/vfc/ default.htm. Accessed November 28, 2008.
17. Merck. Merck Vaccine Patient Assistance Program. 2008. Available at: http://www.merck.com/merckhelps/vaccines/ home.html. Accessed November 28, 2008.
18. Merck. Merck Prescription Discount Program for the Uninsured. 2008. Available at: http://www.merck.com/merckhelps/ uninsured/home.html. Accessed November 28, 2008.
19. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7.
20. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8. (Pubitemid 40590263)
21. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on allHPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102:1-15.
22. Gonik B. Strategies for fostering HPV vaccine acceptance. Infect Dis Obstet Gynecol 2006;2006(suppl):36797.